The Number Needed to Immunize (NNI) to Assess the Benefit of a Prophylaxis Intervention with Monoclonal Antibodies Against RSV

<b>Introduction:</b> Respiratory Syncytial Virus (RSV) is the leading cause of lower respiratory tract infections in infants and children, as well as hospitalizations for respiratory infections in the pediatric population, representing a significant public health concern. Nirsevimab, a long-acting a...

Description complète

Détails bibliographiques

Auteurs principaux:	Sara Boccalini, Veronica Gironi, Primo Buscemi, Paolo Bonanni, Barbara Muzii, Salvatore Parisi, Marta Borchiellini, Angela Bechini
Format:	Artigo
Langue:	Inglês
Publié:	MDPI AG 2025-07-01
Collection:	Vaccines
Sujets:	prevention respiratory syncytial virus number needed to vaccinate children respiratory disease passive immunoprophylaxis
Accès en ligne:	https://www.mdpi.com/2076-393X/13/8/791
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!